Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-08-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2015.61.5187PMID 26304888PMCID PMC4737860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individual prediction of heart failure among childhood cancer survivors.

  2015cited by this paper
• Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

  2015cited by this paper
• Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases

  2015cited by this paper
• Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

  2014cited by this paper
• Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.

  2014cited by this paper
• The EKZ/AMC childhood cancer survivor cohort: methodology, clinical characteristics, and data availability

  2013cited by this paper
• A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.

  2013cited by this paper
• Survivors of childhood and adolescent cancer: life-long risks and responsibilities

  2013cited by this paper
• Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.

  2013cited by this paper
• Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients

  2012cited by this paper
• Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009

  2012cited by this paper
• Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoides

  2012cited by this paper
• The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors.

  2012cited by this paper
• High risk of symptomatic cardiac events in childhood cancer survivors.

  2012cited by this paper
• Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

  2012cited by this paper
• Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.

  2012cited by this paper
• Echocardiographic surveillance for asymptomatic late‐onset anthracycline cardiomyopathy in childhood cancer survivors

  2011cited by this paper
• Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study

  2011cited by this paper
• Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

  2011cited by this paper
• Cardiac Function in 5-Year Survivors of Childhood Cancer—Reply

  2011cited by this paper
• Cardiac function in 5-year survivors of childhood cancer.

  2011cited by this paper
• Anthracycline-induced Cardiac Toxicity More Likely in Underweight Childhood Cancer Survivors

  2010cited by this paper
• Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.

  2010cited by this paper
• Folliculotropic mycosis fungoides: single-center study and systematic review.

  2010cited by this paper
• Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

  2010cited by this paper
• Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.

  2010cited by this paper
• Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases.

  2010cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2010cited by this paper
• CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides

  2009cited by this paper
• Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

  2009cited by this paper
• The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.

  2009cited by this paper
• Overall survival in erythrodermic cutaneous T‐cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T‐cell lymphoma

  2009cited by this paper
• Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study.

  2009cited by this paper
• Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.

  2008cited by this paper
• Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

  2007cited by this paper
• Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

  2007cited by this paper
• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

  2006cited by this paper
• Improved treatment results for childhood acute myeloid leukemia in Taiwan

  2006cited by this paper
• WHO-EORTC classification for cutaneous lymphomas.

  2005cited by this paper
• Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.

  2004cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.

  2004cited by this paper
• Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

  2003cited by this paper
• Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

  2003cited by this paper
• Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients.

  2002cited by this paper
• Anthracycline-induced cardiomyopathy.

  2001cited by this paper
• Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.

  2001cited by this paper
• Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.

  2001cited by this paper
• Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

  2000cited by this paper
• Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

  2000cited by this paper
• Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

  2000cited by this paper
• Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

  2000cited by this paper
• Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

  1999cited by this paper
• Left Ventricular Diastolic Filling Patterns Associated with Progressive Anthracycline-Induced Myocardial Damage: A Prospective Study

  1999cited by this paper
• Analysis of case-cohort designs.

  1999cited by this paper
• Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept.

  1999cited by this paper
• Anthracycline‐induced cardiotoxicity in children with malignancies

  1997cited by this paper
• Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

  1995cited by this paper
• Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?

  1994cited by this paper
• In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.

  1994cited by this paper
• Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.

  1989cited by this paper
• Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study.

  1988cited by this paper
• A case-cohort design for epidemiologic cohort studies and disease prevention trials

  1986cited by this paper
• Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

  1982cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper
• Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

  1977cited by this paper
• A new look at the statistical model identification

  1974cited by this paper
• Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.

  1973cited by this paper

• Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study.

  2025cites this paper
• Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols

  2025cites this paper
• Second Primary Neoplasms in Pediatric Cancer Survivors With Single Institution Experience From Turkey

  2025cites this paper
• Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France

  2025cites this paper
• Vascular Assessment in Adult Survivors of Childhood Cancer

  2025cites this paper
• IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer

  2025cites this paper
• Changing paradigms in pediatric cancer care – the contemporary landscape and perspectives for India

  2025cites this paper
• Incidence, Risk Factors and Early Prediction of Doxorubicin-Induced Cardiotoxicity by Global Longitudinal Strain and Cardiac Biomarkers in Indian Patients With Lymphoma: A Prospective Observational Study.

  2024cites this paper
• Movement efficiency in survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude lifetime cohort study

  2024cites this paper
• Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy

  2024cites this paper
• Autonomic Dysfunction Among Adult Survivors of Childhood Cancer in the St. Jude Lifetime Cohort Study

  2024cites this paper
• Structural Variance of Doxorubicin and Anthracycline Analogues as Topoisomerase Alpha and Beta (Top2a and Top2b) Inhibitors. Potential Design of Analogue Candidates of Less Side Effects on Cardiomyocytes.

  2024cites this paper
• Late subsequent leukemia after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)

  2024cites this paper
• Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century

  2023cites this paper
• Prediabetes and Associated Risk of Cardiovascular Events and Chronic Kidney Disease Among Adult Survivors of Childhood Cancer in the St Jude Lifetime Cohort

  2023cites this paper
• Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades

  2023cites this paper
• Assisted reproductive technology use and outcomes in childhood cancer survivors

  2023cites this paper
• Physical Activity, Fitness, and Cardiovascular Disease Risk in Adolescent Childhood Cancer Survivors Compared to Controls: The Physical Activity in Childhood Cancer Survivors Study

  2023cites this paper
• Survivors of Pediatric Hematopoietic Stem Cell Transplant Exhibit Progressive Diastolic Dysfunction Over Years of Follow-up.

  2023cites this paper
• Systolic myocardial function measured by echocardiographic speckle-tracking and peak oxygen consumption in pediatric childhood cancer survivors—a PACCS study

  2023cites this paper
• Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

  2023cites this paper
• Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

  2023cites this paper
• Cardiac Molecular Remodeling by Anticancer Drugs: Doxorubicin Affects More Metabolism While Mitoxantrone Impacts More Autophagy in Adult CD-1 Male Mice

  2023cites this paper
• Fertility recovery after high-dose melphalan containing regimens

  2023cites this paper
• Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors

  2023cites this paper
• Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

  2023cites this paper
• Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.

  2022cites this paper
• Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study

  2022cites this paper
• Device-measured physical activity and cardiovascular disease risk in adolescent childhood cancer survivors. A physical activity in childhood cancer survivors (PACCS) study

  2022cites this paper
• Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay

  2022cites this paper
• Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: A prospective controlled cross-sectional study.

  2022cites this paper
• Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors

  2022cites this paper
• A novel locus on 6p21.2 for cancer treatment-induced cardiac dysfunction among childhood cancer survivors.

  2022cites this paper
• Questionnaire‐ and linkage‐based outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER study part 1

  2022cites this paper
• A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen

  2022cites this paper
• Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity.

  2022cites this paper
• Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations

  2022cites this paper
• JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia

  2022cites this paper
• Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort

  2021cites this paper
• Progression of Frailty in Survivors of Childhood Cancer: a St. Jude Lifetime Cohort Report.

  2021cites this paper
• Late Outcomes in Survivors of Childhood Acute Myeloid Leukemia: A Report from the St. Jude Lifetime Cohort Study

  2021cites this paper
• Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

  2021cites this paper
• Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor

  2021cites this paper
• Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study

  2021cites this paper
• Heart failure in childhood cancer survivors—a systematic review protocol

  2021cites this paper
• Recomendaciones para el manejo de la cardiotoxicidad relacionada con el tratamiento del cáncer. Primera parte

  2021cites this paper
• Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees.

  2021cites this paper
• Chemotherapie

  2021cites this paper
• How I treat pediatric acute myeloid leukemia.

  2021cites this paper
• Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care

  2021cites this paper
• Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer

  2021cites this paper
• Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas.

  2021cites this paper
• The genetic underpinnings of anthracycline‐induced cardiomyopathy predisposition

  2021cites this paper
• Surveillance for radiation‐related late effects in childhood cancer survivors: The impact of using volumetric dosimetry

  2020cites this paper
• Exercise Intolerance, Mortality, and Organ System Impairment in Adult Survivors of Childhood Cancer.

  2020cites this paper
• Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort

  2020cites this paper
• Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.

  2020cites this paper
• Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging

  2020cites this paper
• High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity

  2020cites this paper
• Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging.

  2020cites this paper
• Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.

  2020cites this paper
• A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.

  2020cites this paper
• Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

  2020cites this paper
• Persistent Variations of Blood DNA Methylation Associated with Treatment Exposures and Risk for Cardiometabolic Outcomes among Long-term Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort

  2020cites this paper
• Epigenetic Age Acceleration and Chronic Health Conditions among Adult Survivors of Childhood Cancer.

  2020cites this paper
• Age-Related Considerations in Cardio-Oncology

  2020cites this paper
• The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.

  2020cites this paper
• The Contribution of Stress and Distress to Cardiovascular Health in Adult Survivors of Childhood Cancer

  2020cites this paper
• Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry

  2020cites this paper
• Cardio-Oncology

  2020cites this paper
• Late Mortality and Chronic Health Conditions in Long-term Survivors of Adolescent and Early Young Adult Cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study

  2020cites this paper
• Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study

  2019cites this paper
• Improved chemotherapy modeling with RAG-based immune deficient mice

  2019cites this paper
• Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study.

  2019cites this paper
• Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study

  2019cites this paper
• Lipophilicity profiling of anthracycline antibiotics by microemulsion electrokinetic chromatography–effects on cardiotoxicity and endotheliotoxicity

  2019cites this paper
• Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study

  2019cites this paper
• Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

  2019cites this paper
• Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: a cross-sectional study

  2019cites this paper
• Surviving Cancer without a Broken Heart

  2019cites this paper
• Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study.

  2019cites this paper
• Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.

  2019cites this paper
• Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes.

  2019cites this paper
• Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study

  2019cites this paper
• In vitro evaluation of anthracycline-induced cardiotoxicity and mitigation by perturbation of angiotensin signalling

  2018cites this paper
• Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

  2018cites this paper
• Risk and Temporal Changes of Heart Failure Among 5‐Year Childhood Cancer Survivors: a DCOG‐LATER Study

  2018cites this paper
• Heart of the matter: reverse takotsubo syndrome in an anthracycline-exposed oncology patient

  2018cites this paper
• Cardiotoxicity of cancer chemotherapy in clinical practice

  2018cites this paper
• Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response.

  2018cites this paper
• Comparison of the pharmacological activity of idarubicin and doxorubicin for retinoblastoma

  2018cites this paper
• Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

  2018cites this paper
• Childhood Cancer Survivor Study Analysis Concept Title: Analysis of Genetic Variants from Candidate Anthracycline-responsive Genes in iPSC- Cardiomyocytes as Predictors of Cardiotoxicity Working Groups: Genetics Chronic Diseases

  2018cites this paper
• Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.

  2018cites this paper
• Clinical challenges in de novo pediatric acute myeloid leukemia

  2018cites this paper
• Childhood Cancer Survivor Study (CCSS) Concept Title: Pathogenesis of anthracycline-related cardiomyopathy in childhood cancer survivors Working Groups: Genetics (primary); Chronic Diseases (secondary); Epidemiology/ Biostatistics (secondary) Roster of Investigators

  2018cites this paper
• Enhance 4′-epidaunorubicin production of engineeringStreptomyces coeruleorubidusstrains via both knockout of daunorubicin-consuming enzymesdnrXanddnrU, and multiple copies of rate-limiting enzymeaveBIV

  2018cites this paper
• Effect of Temporal Changes in Therapeutic Exposure on Self-reported Health Status in Childhood Cancer Survivors.

  2017influential citation
• Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

  2017cites this paper
• Puerarin attenuates the daunorubicin-induced apoptosis of H9c2 cells by activating the PI3K/Akt signaling pathway via the inhibition of Ca2+ influx.

  2017cites this paper